Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting

Analysis by American Society of Clinical Oncology emetogenicity criteria

Harry Raftopoulos, Ralph Boccia, William Cooper, Erin O'Boyle, Richard J. Gralla

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to palonosetron 0.25 mg in preventing acute chemotherapy-induced nausea and vomiting (CINV) after moderately (MEC) or highly emetogenic chemotherapy (HEC) and delayed CINV after MEC, but not superior in preventing delayed CINV after HEC. Emetogenicity was classified by Hesketh criteria; this reanalysis uses newer American Society of Clinical Oncology criteria. Methods: Complete responses (no emesis or rescue medication) after cycle one were reanalyzed after reclassification of MEC and HEC by American Society of Clinical Oncology criteria. Results: APF530 maintained noninferiority to palonosetron. Conclusion: Single-dose APF530 is a promising alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC. The Clinicaltrials.gov identifier for this study is NCT00343460.

Original languageEnglish (US)
Pages (from-to)2541-2551
Number of pages11
JournalFuture Oncology
Volume11
Issue number18
DOIs
StatePublished - Sep 1 2015

Fingerprint

Granisetron
Nausea
Vomiting
Drug Therapy
palonosetron

Keywords

  • APF530
  • cancer
  • chemotherapy-induced nausea and vomiting
  • extended-release
  • granisetron
  • subcutaneous

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting : Analysis by American Society of Clinical Oncology emetogenicity criteria. / Raftopoulos, Harry; Boccia, Ralph; Cooper, William; O'Boyle, Erin; Gralla, Richard J.

In: Future Oncology, Vol. 11, No. 18, 01.09.2015, p. 2541-2551.

Research output: Contribution to journalArticle

@article{c348e0e0fef742238a9143cc7ad1a102,
title = "Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: Analysis by American Society of Clinical Oncology emetogenicity criteria",
abstract = "Background: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to palonosetron 0.25 mg in preventing acute chemotherapy-induced nausea and vomiting (CINV) after moderately (MEC) or highly emetogenic chemotherapy (HEC) and delayed CINV after MEC, but not superior in preventing delayed CINV after HEC. Emetogenicity was classified by Hesketh criteria; this reanalysis uses newer American Society of Clinical Oncology criteria. Methods: Complete responses (no emesis or rescue medication) after cycle one were reanalyzed after reclassification of MEC and HEC by American Society of Clinical Oncology criteria. Results: APF530 maintained noninferiority to palonosetron. Conclusion: Single-dose APF530 is a promising alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC. The Clinicaltrials.gov identifier for this study is NCT00343460.",
keywords = "APF530, cancer, chemotherapy-induced nausea and vomiting, extended-release, granisetron, subcutaneous",
author = "Harry Raftopoulos and Ralph Boccia and William Cooper and Erin O'Boyle and Gralla, {Richard J.}",
year = "2015",
month = "9",
day = "1",
doi = "10.2217/fon.15.185",
language = "English (US)",
volume = "11",
pages = "2541--2551",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "18",

}

TY - JOUR

T1 - Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting

T2 - Analysis by American Society of Clinical Oncology emetogenicity criteria

AU - Raftopoulos, Harry

AU - Boccia, Ralph

AU - Cooper, William

AU - O'Boyle, Erin

AU - Gralla, Richard J.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to palonosetron 0.25 mg in preventing acute chemotherapy-induced nausea and vomiting (CINV) after moderately (MEC) or highly emetogenic chemotherapy (HEC) and delayed CINV after MEC, but not superior in preventing delayed CINV after HEC. Emetogenicity was classified by Hesketh criteria; this reanalysis uses newer American Society of Clinical Oncology criteria. Methods: Complete responses (no emesis or rescue medication) after cycle one were reanalyzed after reclassification of MEC and HEC by American Society of Clinical Oncology criteria. Results: APF530 maintained noninferiority to palonosetron. Conclusion: Single-dose APF530 is a promising alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC. The Clinicaltrials.gov identifier for this study is NCT00343460.

AB - Background: APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to palonosetron 0.25 mg in preventing acute chemotherapy-induced nausea and vomiting (CINV) after moderately (MEC) or highly emetogenic chemotherapy (HEC) and delayed CINV after MEC, but not superior in preventing delayed CINV after HEC. Emetogenicity was classified by Hesketh criteria; this reanalysis uses newer American Society of Clinical Oncology criteria. Methods: Complete responses (no emesis or rescue medication) after cycle one were reanalyzed after reclassification of MEC and HEC by American Society of Clinical Oncology criteria. Results: APF530 maintained noninferiority to palonosetron. Conclusion: Single-dose APF530 is a promising alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC. The Clinicaltrials.gov identifier for this study is NCT00343460.

KW - APF530

KW - cancer

KW - chemotherapy-induced nausea and vomiting

KW - extended-release

KW - granisetron

KW - subcutaneous

UR - http://www.scopus.com/inward/record.url?scp=84942892640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942892640&partnerID=8YFLogxK

U2 - 10.2217/fon.15.185

DO - 10.2217/fon.15.185

M3 - Article

VL - 11

SP - 2541

EP - 2551

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 18

ER -